BTAI Stock Analysis: Buy, Sell, or Hold?
BTAI - BioXcel Therapeutics, Inc. Common Stock
$1.16
-0.03 (-2.52%)
▼
5d:
-11.45%
30d:
-7.94%
90d:
-29.7%
WAIT
LOW Confidence
Analysis Updated: Jun 3, 2026 12:00 AM ET
Earnings: May 18, 2026
0d
Get Alerted When BTAI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
4 traders called BTAI this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: BTAI is down 11.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: BTAI is down 11.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: BTAI is currently trading at $1.16, which is considered extended relative to its 30-day fair value range of $1.10 to $1.25.
Technical Outlook: Technically, BTAI is in a strong downtrend. Immediate support is located at $1.07, while resistance sits at $1.42.
Market Sentiment: BTAI has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $14.00 (+1106.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, BTAI is in a strong downtrend. Immediate support is located at $1.07, while resistance sits at $1.42.
Market Sentiment: BTAI has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $14.00 (+1106.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$1.10 -
$1.25
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 1106.9% below Wall St target ($14.00)
- WARNING: Recommendation downgraded due to -11.5% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$1.10 -
$1.25
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$1.07
Resistance Level
$1.42
Current Trend
Strong Downtrend
Technical data as of
Jun 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.75
Wall Street Target
$14.00
(+1106.9%)
Revenue Growth (YoY)
22.6%
Share & Embed Analysis
Last updated: June 03, 2026 6:31 PM ET
Data refreshes hourly during market hours. Next update: 7:31 PM
Data refreshes hourly during market hours. Next update: 7:31 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BTAI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$192 | 66 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$125 | 60 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$104 | 56 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 58 HOLD |
|
HCM
HUTCHMED DRC |
STRONG BUY
14 analysts |
$23 | 55 HOLD |
